Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline in key areas of unmet need related to cancer. The Company's lead product candidate, entinostat, a once-weekly, oral, small molecule, class I HDAC inhibitor, is being tested in a Phase 3 combination trial with exemestane for treatment of advanced HR+, HER2- breast cancer.